TNF Inhibitors Reduce Risk of Cardiovascular Events Associated With Rheumatoid Arthritis

TNF inhibitors used to treat rheumatoid arthritis reduce the risk of myocardial infarction (heart attack) and cerebrovascular accidents (stroke) compared to patients treated with traditional DMARDs, according to new study results presented at the Annual European Congress of Rheumatology (EULAR).

It is already known that rheumatoid arthritis patients have an increased risk of premature mortality from cardiovascular disease. The new results are encouraging because TNF inhibitors may reduce the risk of mortality in rheumatoid arthritis patients. Researchers suggest it may be the anti-inflammatory effect of TNF inhibitors which reduce the risk of cardiovascular events in rheumatoid arthritis patients.

• TNF Inhibitors (Enbrel, Remicade, Humira) - Test Your Knowledge
• Guide to Rheumatoid Arthritis
• Unsuitable Candidates For Biologic Drugs
• Fearing Side Effects of Enbrel, Remicade, Humira
• Inflammation Elevates Risk of Cardiac Death in Rheumatoid Arthritis Patients

_{Photo © ADAM}